ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Parexel Named “Best Contract Research Organization” at 19th Annual Scrip Awards

DURHAM, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced today announced it has been named “Best Contract Research Organization” in the Full-Service Provider category at the 19th Annual Scrip Awards. The Best CRO ranking from Scrip follows the company’s recognition earlier in the year as Top CRO to Work With in the 2023 WCG CenterWatch Global Site Relationship Benchmark Survey and winner of the 2023 Society for Clinical Research Sites (SCRS) Eagle Award recognizing the CRO committed to advancing the clinical research profession through strong site partnerships.  

“Parexel colleagues are passionate about developing life-changing new therapies to advance world health,” said Chief Executive Officer Jamie Macdonald. “This exciting recognition is a true testament to their efforts and collaboration with our customers, sites and partners across the clinical research enterprise to make a difference for patients. We remain committed to innovating across Phase I to IV clinical development to drive research forward and make clinical trial participation more accessible and inclusive for all.” 

The annual Scrip Awards, organized by Citeline, the leading provider of drug, device, company, clinical trial and market intelligence in the pharmaceutical and medtech markets, are designed to celebrate and recognize the very best innovations and achievements in global biopharma. Winners were named across 14 categories, including Best Contract Research Organization, which recognizes the critical role CROs play in the drug development process. Parexel was selected by a distinguished panel of life science industry executives based on the company’s capabilities and strengths in delivering results to exceed sponsor expectations; innovations in patient engagement and recruitment; commitment to diversity and inclusion in clinical trials and ability to leverage AI and RWE to evolve the clinical development process to better serve patients. Parexel was recognized at the Scrip Awards ceremony Nov. 16 in London. 

About Parexel
Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more than 21,000 global professionals works in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind, increasing access and participation to make clinical research a care option for anyone, anywhere. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas, while our innovation ecosystem offers the best solutions to make every phase of the clinical trial process more efficient. With the people, insight and focus on operational excellence, we work With HeartTM every day to treat patients with dignity and continuously learn from their experiences, so every trial makes a difference. For more information, visit parexel.com and follow us on LinkedIn, Twitter,Facebook and Instagram

MEDIA
Lori Preuit Dorer
+1 513 496 8121
Lori.Dorer@parexel.com

Danaka Williams
+1 984 298 4207
Danaka.Williams@parexel.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  229.53
+0.42 (0.18%)
AAPL  278.78
-1.92 (-0.68%)
AMD  217.97
+1.99 (0.92%)
BAC  53.95
+0.07 (0.13%)
GOOG  322.09
+3.70 (1.16%)
META  673.42
+11.89 (1.80%)
MSFT  483.16
+2.32 (0.48%)
NVDA  182.41
-0.97 (-0.53%)
ORCL  217.58
+3.25 (1.52%)
TSLA  455.00
+0.47 (0.10%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.